|
Market Closed -
Nasdaq
16:00:00 2026-10-12 EDT
|
5-day change | 1st Jan Change | ||
| 0.9375 USD | -5.59% |
|
-2.40% | -82.54% |
| 09-23 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 168.8 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -82.32% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 18.83 | 35.83 | 52.83 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -98.03% | 90.27% | 47.44% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -1.89x | -1.68x | -2.13x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | 235x | - | - | 25.9x | 3.77x |
| EV / Revenue | - | - | - | 85.6x | - | - | 5.5x | 1.18x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -0.19x | -0.32x | -0.42x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -0.19x | -0.32x | -0.51x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -0.26x | -0.37x | -0.56x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -386% | -267% | -180% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.496 | -0.5586 | -0.44 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | - | 6.512 | 44.82 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -99.95 | -111.9 | -124.7 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -98.56 | -113 | -102.6 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -93.27 | -111.7 | -93.5 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -133 | -116 |
| Reference price 2 | 3.1700 | 5.0300 | 1.5600 | 1.4500 | 5.3700 | 0.9375 | 0.9375 | 0.9375 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 3/18/22 | 3/15/23 | 3/21/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2x | - | -0.29x | - | 179M | |
| 20.5x | 7.33x | 14.72x | 1.45% | 70.61B | |
| 27.46x | 7.51x | 23.56x | 0.05% | 51.01B | |
| 33.37x | 6x | 17.96x | 0.97% | 48.1B | |
| 33.47x | 3.25x | 14.03x | -.--% | 42.78B | |
| -19.64x | 203.45x | -20.92x | -.--% | 40.67B | |
| 46.95x | 5.34x | 29.33x | -.--% | 40.3B | |
| 27.18x | 7.73x | 20.09x | 0.42% | 30.59B | |
| 32.53x | 6.94x | 18.03x | -.--% | 28.16B | |
| -14.69x | 5.97x | -7.21x | -.--% | 24.36B | |
| Average | 18.51x | 28.17x | 10.93x | 0.32% | 37.68B | |
| Weighted average by Cap. | 22.21x | 27.61x | 13.23x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
